CJC-1295
CJC-1295 needs a defined molecular variant before a reference mass or experimental finding can be applied. In particular, establish whether the material includes the albumin-reactive modification associated with the long-acting research construct. A shortened product name cannot resolve that distinction.
Identify the construct
| Field | Required clarification |
|---|---|
| Sequence | Exact peptide backbone and substitutions |
| Terminal chemistry | Groups present at each end |
| Modification | Linker or albumin-reactive group, if present |
| Supplied form | Salt and other specified constituents |
| Expected identity | Theoretical entity and suitable analytical confirmation |
Jetté and colleagues studied albumin-linked growth-hormone-releasing-factor analogues. The modification is part of the entity studied, not a detachable marketing adjective. [1]
Read long-acting research for its actual material
Teichman and colleagues investigated a long-acting CJC-1295 construct in healthy adults and reported pharmacokinetic and hormonal endpoints. Those results belong to that defined material and study design. They cannot be transferred to an unresolved “without DAC” product or to a two-component blend. [2]
The DAC comparison explains the naming problem. The half-life modification guide distinguishes pharmacokinetic measurements from storage stability.
The catalogue question is specific
The CJC-1295/ipamorelin blend names two components. Its CJC component needs a written variant definition. The component amount and analytical evidence must then refer to that same entity. A total blend fill does not establish either component's identity.
Reconcile the certificate before using a reference value
Compare the specification's sequence, modification and form with the identity result and report scope. If the report names only CJC-1295, ask how the method and expected result distinguish the relevant variants. Keep an unresolved field visible rather than filling it from a different supplier's page.
Use batch documentation for the lot record and CJC versus ipamorelin for the component distinction. No variant, molar mass, half-life or personal-use schedule is inferred here from the abbreviated catalogue name.
Use the Certificate of Analysis guide to read the report's method, result and qualification fields alongside that identity check.
Continue the material check
| Resource | Why open it |
|---|---|
| Receptor-Targeted Research Peptides | Browse receptor-related materials with variant limits visible. |
| Compound Index | Find another molecular profile without confusing it with a vial. |
| Co-Formulated Research Blends | Find the two blend records and their component-evidence questions. |
Sources and scope
- Jetté et al. (2005). Albumin-linked GRF analogues in rats. Endocrinology.Albumin-reactive construct is essential to identity; no half-life transfer to unresolved/no-DAC material. Access: Original article abstract retrieved through official Europe PMC core record
- Teichman et al. (2006). Long-acting CJC-1295 in healthy adults. JCEM.Two healthy-adult trials of long-acting construct; 5.8–8.1-day half-life is not storage stability or a blend protocol. Access: Original article abstract retrieved through official Europe PMC core record